Evidence map›Paper›PMID 31754927›Full record

ArticleAngiogenesis2020

The potassium channel Kcne3 is a VEGFA-inducible gene selectively expressed by vascular endothelial tip cells.

Ron A Deckelbaum, Ivan B Lobov, Eunice Cheung, Gabor Halasz, Saathyaki Rajamani, Julia Lerner, Chunxiang Tong, Zhe Li, Patricia Boland, Melissa Dominguez and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Angiogenesis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. The role and mechanisms of microvascular damage in the ischemic myocardium.Cellular and molecular life sciences : CMLS · 2023
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Ron A DeckelbaumDepartment of Pre-Therapeutic Target Discovery, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 10591, USA. ron.deckelbaum@regeneron.com.ORCID 0000-0003-1028-3019
Ivan B LobovPalmira Biopharma, Moscow, 143026, RF, Russia.
Eunice CheungDepartment of Ophthalmology, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 10591, USA.
Gabor HalaszDepartment of Bioinformatics, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 10591, USA.
Saathyaki RajamaniDepartment of Pre-Therapeutic Target Discovery, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 10591, USA.
Julia LernerDepartment of Pre-Therapeutic Target Discovery, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 10591, USA.
Chunxiang TongDepartment of Pre-Therapeutic Target Discovery, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 10591, USA.
Zhe LiDepartment of Oncology & Angiogenesis, Regeneron Pharmaceuticals Inc., Tarrytown, NY, 10591, USA.
Patricia BolandDepartment of Oncology & Angiogenesis, Regeneron Pharmaceuticals Inc., Tarrytown, NY, 10591, USA.
Melissa DominguezDepartment of Pre-Therapeutic Target Discovery, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 10591, USA.
Virginia HughesDepartment of Pre-Therapeutic Target Discovery, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 10591, USA.
George D YancopoulosDepartment of Research, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 10591, USA.
Andrew J MurphyDepartment of Research, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 10591, USA.
Gavin ThurstonDepartment of Oncology & Angiogenesis, Regeneron Pharmaceuticals Inc., Tarrytown, NY, 10591, USA.
Jingtai CaoDepartment of Ophthalmology, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 10591, USA.
Carmelo RomanoDepartment of Ophthalmology, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 10591, USA.
Nicholas W GaleDepartment of Pre-Therapeutic Target Discovery, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 10591, USA.
Regeneron (United States) · USTarget (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angiogenesis is largely driven by motile endothelial tip-cells capable of invading avascular tissue domains and enabling new vessel formation. Highly responsive to Vascular Endothelial Growth-Factor-A (VEGFA), endothelial tip-cells also suppress angiogenic sprouting in adjacent stalk cells, and thus have been a primary therapeutic focus in addressing neovascular pathologies. Surprisingly, however, there remains a paucity of specific endothelial tip-cell markers. Here, we employ transcriptional profiling and a lacZ reporter allele to identify Kcne3 as an early and selective endothelial tip-cell marker in multiple angiogenic contexts. In development, Kcne3 expression initiates during early phases of angiogenesis (E9) and remains specific to endothelial tip-cells, often adjacent to regions expressing VEGFA. Consistently, Kcne3 activation is highly responsive to exogenous VEGFA but maintains tip-cell specificity throughout normal retinal angiogenesis. We also demonstrate endothelial tip-cell selectivity of Kcne3 in several injury and tumor models. Together, our data show that Kcne3 is a unique marker of sprouting angiogenic tip-cells and offers new opportunities for investigating and targeting this cell type.

Indexed as

AnimalsAnimals, NewbornCell DifferentiationCells, CulturedDiabetic RetinopathyEmbryo, MammalianEndothelial CellsFemaleGene Expression Regulation, DevelopmentalMiceMice, 129 StrainMice, Inbred C57BLMice, TransgenicMorphogenesisNeovascularization, PathologicNeovascularization, PhysiologicKcne3 protein, mousePotassium Channels, Voltage-GatedVascular Endothelial Growth Factor Avascular endothelial growth factor A, mouseEndothelial tip-cellKcne3Retinal angiogenesisVEGFA

Identifiers

PMID31754927
PMCPMC7160073
OpenAlexW2991349919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.